Volume 17, Number 10—October 2011
CME ACTIVITY - Research
Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009
Table 1
Characteristics of screened susceptible and resistant isolates of Aspergillus spp., the Netherlands, 2007–2009*
Source and species | No. (%) susceptible, n = 1,978 | No. (%) resistant, n = 84 |
---|---|---|
Specimen source | ||
Sputum | 1,397 (70.6) | 64 (76.2) |
Ear swab | 176 (8.9) | 3 (3.6) |
BAL fluid | 97 (4.9) | 6 (7.1) |
Bronchus secretion | 66 (3.3) | 2 (2.4) |
Throat/nasal swab | 66 (3.3) | 1 (1.2) |
Tissue | 55 (2.8) | 5 (6.0) |
Skin swab/nail | 38 (1.9) | 1 (1.2) |
Mouth wash | 26 (1.3) | 1 (1.2) |
Pus/wound swab | 16 (0.8) | 1 (1.2) |
Bronchial wash | 11 (0.6) | 0 |
Feces | 8 (0.4) | 0 |
Unknown | 22 (1.1) | 0 |
Species | ||
A. fumigatus | 1,710 (86.5) | 82 (97.6) |
A. flavus | 98 (5.0) | 0 |
A. niger | 52 (2.6) | 2 (2.4) |
A. terreus | 35 (1.8) | 0 |
A. nidulans | 14 (0.7) | 0 |
A. versicolor | 13 (0.7) | 0 |
A. glaucus | 6 (0.3) | 0 |
Unknown | 50 (2.5) | 0
*BAL, bronchoalveolar lavage. *BAL, bronchoalveolar lavage. |
*BAL, bronchoalveolar lavage.